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Abstract
The first genome wide association study (GWAS) for childhood asthma identified a novel major susceptibility locus on
chromosome 17q21 harboring the ORMDL3 gene, but the role of previous asthma candidate genes was not specifically
analyzed in this GWAS. We systematically identified 89 SNPs in 14 candidate genes previously associated with asthma in .3
independent study populations. We re-genotyped 39 SNPs in these genes not covered by GWAS performed in 703
asthmatics and 658 reference children. Genotyping data were compared to imputation data derived from Illumina
HumanHap300 chip genotyping. Results were combined to analyze 566 SNPs covering all 14 candidate gene loci.
Genotyped polymorphisms in ADAM33, GSTP1 and VDR showed effects with p-values ,0.0035 (corrected for multiple
testing). Combining genotyping and imputation, polymorphisms in DPP10, EDN1, IL12B, IL13, IL4, IL4R and TNF showed
associations at a significance level between p=0.05 and p=0.0035. These data indicate that (a) GWAS coverage is
insufficient for many asthma candidate genes, (b) imputation based on these data is reliable but incomplete, and (c) SNPs in
three previously identified asthma candidate genes replicate in our GWAS population with significance after correction for
multiple testing in 14 genes.
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Introduction
Genome wide association studies (GWAS) have recently
identified genetic susceptibility for many complex diseases by
genotyping hundreds of thousands of single nucleotide polymor-
phisms (SNPs) across the genome in very large sets of patients and
controls [1]. While GWAS discovered novel disease loci, many
previous candidate genes identified by hypothesis driven ap-
proaches were not replicated by GWAS at a genome wide
significance level. Thus, the question arose in many complex
disorders if associations with previous candidate genes represent
false positive results. Alternatively it was suggested that GWAS
SNP chips insufficiently covered these genes of interest. Imputa-
tion was recently introduced to predict allelic status of SNPs not
covered by direct genotyping in GWAS, extrapolating information
from neighbouring SNPs for which genotyping data and linkage
disequilibrium (LD) from HapMap was available. The value of
these approaches is not yet determined. We used our GWAS data
set on asthma [2] to study these open questions specifically for
candidate genes in asthma.
Inchildhoodasthma,thefirstGWAS[2]towhichwecontributed
a discovery population of app. 1.400 German children, captured a
major susceptibility signal from chromosome 17q21 and a few less
suggestive hits in other regions of the genome, none of which was
overlapping with the numerous asthma candidate genes previously
identified by hypothesis driven approaches or positional cloning [3].
Therefore, we developed bioinformatics tools to systematically
identify asthma candidate genes from the literature and genotyped
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e13894these genes for previously suggested asthma related SNPs. We
compared these results with the initial GWAS genotyping and
imputation data derived from our original GWAS genotyping [2].
We used the combination of these approaches to cover all
candidate genes in depth with tagging SNPs and performed a
comprehensive analysis of previous candidate gene loci.
Results
We implemented a script to scan an assemblage of abstracts for
specific gene names or collections of gene names as depicted in
figure 1a. The script searches for single words or specific groups of
words in a given text. Gene names or a group of several names for
the same gene were searched in a collection of abstracts. For every
gene name or cluster of gene names respectively a separate file was
produced that consists of all abstracts a gene of the cluster is
mentioned in. Gene names and symbols were obtained from the
Human Genome Organization - Gene Nomenclature Committee
[4]. We scanned all 28,472 approved symbols in the HUGO
database as of October 22
nd 2009. If available we clustered these
gene names with their previous symbols and their attached
aliases so that overall 98743 specific gene names were searched
against a selection of abstracts published in the pubmed database
(http://www.pubmedcentral.nih.gov/) as of October 22
nd 2009.
For the current study we searched for the terms ‘‘asthma’’ and
‘‘association’’ and ‘‘SNP’’ or ‘‘polymorphism’’ or ‘‘genetic’’,
retrieving 1,341 abstracts. With the script 825 cluster of gene
names, hence genes, were extracted. Details on the use of the
bioinformatics search tool for genetic association data from the
literature are available upon request from the authors. All
abstracts were then examined to contain significant associations
(nominal p-value of ,0.05) with asthma. For that purpose,
different forms of asthma like childhood, adult or atopic asthma
were not discriminated and reports were not weighted for study
size. Associations with asthma severity or intermediate phenotypes
of asthma were not considered and the analysis was restricted to
studies in English language. All genes for which genetic
associations with asthma were reported at the gene level in a
discovery dataset and at least three independent populations (not
necessarily published independently) were studied further. Direc-
tion of association and associated SNP in a gene could vary (loose
replication) as indicated in table 1. Genes discovered by further
GWAS studies [5,6] were excluded in this study as their discovery
relied on SNPs present at currently used SNP chips.
The most prevalent gene symbol in the retrieved abstracts for
genetic association with asthma was IL4 (91 citations) followed by
IL13 (75 citations) and TNF (73 citations). Significant associations of
SNPs in IL4 with asthma were reported in 15 different populations.
Thefollowing14genesdistributedacrossthegenomewereassociated
with asthma diagnosis in more than three independent study
populations (figure 1b): ADAM33, CCL5, CD14, DPP10, EDN1,
GPR154, GSTP1, IL12B, IL13, IL4, IL4R, PTGDR, TNF,a n dVDR.
In these genes, asthma association had been reported for a total
of 89 SNPs (table 2 and table S1); only 19 of these had been
directly genotyped by the Illumina Sentrix HumanHap300
BeadChip used in our GWAS. Using linkage disequilibrium
(LD) based on HapMap [7], a further 14 of these 89 SNPs were
indirectly covered by tagging SNPs from chip-genotyping. Thus,
only a total of approximately 37% of previously suggested SNPs in
asthma candidate genes were captured directly or indirectly by
GWAS genotyping. None of the SNPs in ADAM33, CCL5, CD14,
or IL4 (table 2) were covered by the original GWAS genotyping.
We aimed at re-genotyping all additional candidate gene SNPs
and performed imputation based on GWAS genotyping. From 56
SNPs not covered be GWAS genotyping, genotyping assays could
be designed for 45 of which 39 passed quality control. For 58 of
the 89 candidate-gene derived SNP imputation was successful.
Thus, for 11 of the 89 SNPs only imputation but no genotyping
data and for 55 candidate SNPs (with previous association)
imputation and genotyping data were available. In cases where
both imputation and genotyping results were available for a
specific SNP, genotyping results were always used for further
analyses. Using GWAS genotyping data, re-genotyping and
imputation in combination, data for 83 out of 89 candidate gene
SNPs from the literature could be analyzed successfully.
SNPs in the genes ADAM33 (rs528557, p=0.000019) and VDR
(rs1540339, p=0.0014), previously associated with asthma, were
also associated with asthma in this dataset at a significance level of
0.0035 corrected for multiple testing. Previously associated SNPs
in EDN1, IL13, IL4R and TNF replicated at a nominal significance
level between 0.05$p.0.0035. Effect size and effect directions
were compared to previously published results in table 1.
For 241 SNPs in the 14 candidate genes both imputation and
direct genotyping data were available irrespective of previously
reported associations (table S2). Effect size and p-value of effects
correlated tightly (figure 2), and R
2 is given in table S2. Direction
of effects changed 12 times, mostly when effects were close to 1.
However, in one case (rs2280788, CCL5) imputation implied an
odds ratio (OR) of 0.75 when re-genotyping showed an effect size
of 1.22. For IL4, imputation suggested rs2070874 (C-33T) to be
significantly associated with asthma (p=0.005) but the association
was not significant when re-genotyped by matrix-assisted laser
desorption/ionization time-of flight (MALDI-TOF) (p=0.054).
An opposite outcome was observed for IL4R rs2057768, when an
effect was significant by genotyping but not by imputation
(p=0.009 versus p=0.2). This suggests that imputation is a
reasonably reliable tool to estimate SNP effects of asthma
candidate genes based on 1
st generation GWAS genotyping data,
when effect sizes are beyond 1.25 in a population of app. 1,000
cases. For detailed comparison between re-genotyped and
inputated SNPs see figure 3. However, imputation based on
GWAS BeadChip genotyping data could only increase coverage of
the previously reported SNPs in asthma candidate genes to app.
60%; missing numerous SNPs of specific interest.
Thus, we next combined data from 1
st generation GWAS
genotyping by BeadChip, re-genotyping by MALDI-TOF and
TaqManH MGB, and imputation based on this combined set of
genotypes to comprehensively saturate all 14 candidate gene loci
under study with 566 tagging SNPs as well as previously associated
SNPs (figure 4 and table S2). This way, further associations below
the 0.0035 threshold were detected for SNPs in GSTP1 and VDR.
Further SNPs in DPP10, IL12B and IL4 were now found to be
associated with asthma in our population, but only at the nominal
significance level of 0.05 (table S2).
Discussion
We systematically investigated the role of SNPs from previously
suggested asthma candidate genes with more than three positive
association reports in the literature. In a large German population
for which 1
st generation GWAS was also available, imputation was
provided based on Illumina Sentrix HumanHap300 BeadChip
data and compared to re-genotyping of candidate gene SNPs by
MALDI-TOF and TaqManH techniques. Thus, an in depth
analysis of these previously suggested candidate genes was
performed. The study was powered to detect asthma odds ratios
of 1.5 at a significance level of alpha=0.05 with a power of 95%
for SNPs with a minor allele frequency of .0.1 and for odds ratios
GWAS, Candidates and Asthma
PLoS ONE | www.plosone.org 2 November 2010 | Volume 5 | Issue 11 | e13894Figure 1. a) Schematic depiction of literature query process. * genes not further investigated were (a) ORMDL3, originally discovered in this
GWA; (b) discovered by other GWAS: CHI3L1, IL1RL1, MYB, WDR36 (c) NOS1 where CA-repeats and not SNPs were reported; (d) gene deletions for
GSTM1, FLG. b) Number of populations that show an association between SNPs in the 14 selected candidate genes and asthma
diagnosis. (based on literature query from October 22
nd 2009).
doi:10.1371/journal.pone.0013894.g001
GWAS, Candidates and Asthma
PLoS ONE | www.plosone.org 3 November 2010 | Volume 5 | Issue 11 | e13894of 1.3 with a power of 80%. SNPs in three of 14 investigated
candidate genes showed associations at a significance level
corrected for multiple testing (p,0.0035), and further 7 genes
were associated at a significance level of p,0.05. Effect directions
were consistent for associated SNPs in our population compared to
previous publications in populations of similar ancestry (table 1).
We expected to observe less than five positive associations at a
nominal significance level of p,0.05 under the null hypothesis of
Table 1. Comparison of risk allele, frequency of risk allele in cases and controls and effect size in our study population and
previously published studies for candidate gene polymorphisms with a p- value of ,0.05 in our population (for complete results
on all tested SNPSs see table S2).
current study summary of previous published results
gene &
SNP rs nr
risk
allele
freq cases/
controls
Odds ratio
(95%CI)
study, reference, origin, and n
of cases (freq cases/freq controls)
risk
allele
odds ratio
(95%CI)
ADAM33 rs528557 G 0.29/0.22 1.51 (1.25–1.82) Thongngarm et al.
[19] + Thai n=200 (0.24/0.18) C 1.94 (1.16–3.26)
Eerdewegh et al.
[20]+ Caucasian n=130 (0.84/0.73) G 1.93 (1.08–3.56)
Howard et al.
[21] Hispanic n=111 (0.23/0.17) C 1.38 (1.00–3.23)
Howard/Afric Amer n=157 (0.70/0.63) C 1.79 (1.04–2.44)
Hirota et al.
[22]+ Japanese n=482 (0.79/0.75) G 1.25 (1.02–1.54)
Blakey et al.
[23] British n=1306 (0.75/0.73) C 1.09 (1.01–1.16)
EDN1 rs5369 G 0.89/0.86 1.36 (1.04–1.72) Zhu et al.
[24] Norwegian n=267 (0.11
++) A A risk allele*
EDN1 rs1629862 G 0.89/0.86 1.32 (1.04–1.64) Zhu/British n=907 (0.90
++) G G risk allele*
Zhu/Norwegian n=267 (0.90
++) G G risk allele*
IL13 rs20541 A 0.24/0.21 1.23 (1.03–1.48) Black et al.
[25] + British n=275 (0.22/0.17) A 1.39 (1.11–1.73)
Heinzmann et al.
[26] Japanese n=100 (0.63/0.43) A 1.81 (1.11–2.93)
Heinzmann/British n=150 (0.40/0.27) A 2.14 (1.28–3.60)
Hosseini-Farahabadi et al.
[27] + Iranian n=30 (0.41/0.22) A 2.52 (1.19–5.40)
IL4R rs2057768 T 0.30/0.25 1.27 (1.06–1.51) Hytonen et al.
[28] Swedish n=170 (0.21
++) T T risk haplo**
IL4R rs1805010 G 0.48/0.43 1.23 (1.05–1.45) Zhang et al.
[29] Chinese n=352
+++ (0.46/0.38) A 1.38 (1.01–1.88)
Beghe et al.
[30] British =326 (0.45
++) A A risk haplo**
Zhang et al.
[31] Chinese n=145 (0.49
++) G G risk haplo**
Zhang/Malasian n=73 (0.47
++) G G risk haplo**
Ober et al.
[32] Hutterite n=77 (0.48
++) G G risk haplo**
Hytonen et al.
[28] Swedish n=170 (0.47
++) G G risk haplo**
TNF rs1800629 A 0.18/0.14 1.34 (1.08–1.66) Li et al.
[33] Californian n=403 (0.13
++) A 1.25 (1.11–1.43)
Castro-Giner et al.
[34] European n=278 (0.21/0.15) A 1.49 (1.22–1.81)
Wu et al.
[35] Mexican n=596 (0.05/NA) A 1.54 (1.04–2.28)
Munthe-Kaas et al.
[36] Norwegian n=268 (NA) A 1.6 (1.2–2.0)
Kim et al.
[37] Korean n=719 (0.07/0.04) A 1.77 (1.05–2.82)
Kumar et al.
[38] + Indian n=155 (0.14/0.08 A 1.79 (1.01–2.98)
Witte et al.
[39] mixed American n=236 (0.16/0.13) A 1.86 (1.03–3.34)
Kumar et al
[40] Indian n=123 (0.16/0.09) A 1.9 (1.31–2.49)
Wang et al.
[41] Taiwanese n=140 (0.15/0.07) A 2.17 (1.29–4.33)
Jime ´nez-Morales et al
[42] Mexican n=226 (0.06/0.03) A 2.32 (1.28–4.20)
Winchester et al.
[43] British/Irish n=20 (0.43/0.18) A 2.6 (1.1–6.2)
Chagani et al.
[44] Caucasian n=251 (NA) A 3.07 (1.1–5.5)
Moffat et al.
[45] Australian n=92 (0.3/0.18) A 3.57 (2,17–10.42)
Shin et al.
[46] Korean n=550 (0.95/0.88) G 2.7 (1.56–4.76)
Albuquerque et al.
[47] Caucasian n=74 (0.83/0.77) G 2.38 (1.3–4.55)
VDR rs1540339 G 0.65/0.59 1.28 (1.10–1.49) Poon et al.
[48] Quebecian n=347 (0.4
++) A A risk allele*
VDR rs3782905 C 0.32/0.28 1.21 (1.02–1.44) Raby et al.
[49] + European ancestry n=517 (0.33/0.28) C 1.26 (1.03–1.53)
Poon et al.
[48] Quebecian n=347 (0.31
++) C C risk allele*
+The OR and confidence intervals were calculated based on published data.
++Allele frequency of the entire study is provided if separate allele frequencies were not applied or haplotype or family studies have been conducted.
+++In the Chinese population the G allele is the major allele.
*Allele is either announced as the risk allele or described to be overtransmitted to asthmatic patients.
**The haplotype containing this allele is associated with the susceptibility to asthma.
doi:10.1371/journal.pone.0013894.t001
GWAS, Candidates and Asthma
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with asthma at this level, twice more than expected by chance. We
corrected for multiple testing by multiplying the nominal
significance level of alpha=0.05 by the number of genes studied
(N=14). This seems appropriate for the purpose of replication
testing. When extending the analyses to all 566 SNPs in the
respective gene locus, this level of correction may be too
permissive. Also, one has to keep in mind that novel associations
found with the broader approach of saturating tagging SNPs lack
the level of replication which the SNPs drawn from the literature
have already achieved. Therefore, the associations found with
rs614080 and rs6591256 in GSTP1, rs17764121, rs1396936,
rs966859, rs17823623, rs12997234 and rs13034936 in DPP10,
rs3213102 in IL12B and rs2243274 in IL4 need to be treated with
caution until a sufficient level of replication has been achieved for
these SNPs in other populations.
Imputation was compared to re-genotyping in our dataset to
assess the usefulness of imputation to answer such a specific
question as to what extent certain candidate gene SNPs play a role
in asthma in a GWAS data set. Clearly, accuracy of imputation
depends on coverage of the specific locus under investigation.
With 1
st generation GWAS SNP chips, gray and black areas with
low or no SNP coverage exist in the genome (table S3).
Interestingly, this is also the case for well known genes associated
with many diseases: For CD14 and IL4, no SNP was genotyped by
the Illumina Sentrix HumanHap300 BeadChip. This has
improved for later versions of GWAS genotyping chips (table
S3). But still, the coverage of putatively functional SNPs previously
associated with disease is insufficient for many genes even in next
generation GWAS chips and even when tagging SNP approaches
based on LD were taken into account (table S3).
LD for our imputation was derived from HapMap2 version
2006 as well as HapMap3 version 2009. With further improve-
ments of HapMap and the finalisation of the 1000 Genomes
project, where 1000 human genomes are currently being
sequenced (www.1000genomes.org), imputation information also
on existing SNP sets will improve and re-analysis of existing
Table 2. Number of previously associated asthma candidate gene SNPs and coverage by 1
st generation GWAS genotyping,
imputation and re-genotyping.
gene chromosome
N of SNPs with
reported
association
GWAS genotyping *
(genotyped directly/
tagged indirectly)
imputation HapMapII **
(genotyped directly/
tagged indirectly)
imputation HapMap III **
(genotyped directly/
tagged indirectly) re-genotyped ***
ADAM33 20p13 18 0/0 6/0 6/0 14[2]
CCL5 17q11 2 0/0 1/0 1/0 2
CD14 5q31 2 0/0 2/0 1/0 1
DPP10 2q12 5 0/4 5/0 3/0 0
EDN1 6p24 9 2/3 6/1 5/0 0[2]
GPR154 7p15 12 3/2 9/0 4/0 5[1]
GSTP1 11q13 2 1/0 1/0 1/0 1
IL12B 5q31 5 2/0 5/0 4/0 1
IL13 5q31 3 1/0 1/0 2/0 2
IL4 5q31 3 0/0 2/0 3/0 2
IL4R 16p12 8 4/1 6/0 7/0 2[1]
PTGDR 14q22 6 1/2 2/1 2/0 3
TNF 6p21 5 0/1 3/0 3/0 3[1]
VDR 12q12 9 5/1 7/0 7/0 3
sum of SNPs 89 33 (19/14) 58 (56/2) 49 39[7]
*on Illumina Sentrix HumanHap300 BeadChip.
**based on Illumina Sentrix HumanHap300 BeadChip and Hapmap phase II or III respectively.
***by MALDI-TOF or TAQMAN.
[ ] indicates SNPs for which genotyping failed.
doi:10.1371/journal.pone.0013894.t002
Figure 2. Correlation between effect sizes observed by
concomitant genotyping and imputation of candidate gene
SNPs for which both measures were available. (red indicates
change of effect direction between genotyping and imputation). For
the comparison based on HapMapII (HM2) data 241 SNPs and for
HapMapIII (HM3) 216 SNPs were available.
doi:10.1371/journal.pone.0013894.g002
GWAS, Candidates and Asthma
PLoS ONE | www.plosone.org 5 November 2010 | Volume 5 | Issue 11 | e13894Figure 3. Comparison of effect sizes and p-values derived from regenotyped SNPs with data based on imputation. Log transferred p-
values are shown on the y-axis. Each individual SNP effect is depicted as a circle where the diameter of the circle reflects the respective odds ratios.
The dark grey circles represent the regenotyping the light grey circles stand for the imputation based on HapMap2 and the transparent show the
imputation data based on HapMap3. Significance level are marked as solid (p=0.05) and dashed grey lines (p=0.0035).
doi:10.1371/journal.pone.0013894.g003
Figure 4. Association of 566 tagging SNPs in 14 candidate genes with asthma. Genes are positioned along the x-axis in alphabetical order.
Each dot represents SNPs in their relative position within the gene. Log transferred p-values are shown on the y-axis. Each individual SNP effect is
depicted as a circle where the diameter of the circle reflects the respective odds ratios. Significance level are marked as solid (p=0.05) and dashed
green lines (p=0.0035).
doi:10.1371/journal.pone.0013894.g004
GWAS, Candidates and Asthma
PLoS ONE | www.plosone.org 6 November 2010 | Volume 5 | Issue 11 | e13894GWAS data may be useful. Despite it’s known limitations,
imputation proved valuable and helpful in this project. Reliability
of results was satisfactory when compared to real genotyping
results in those cases where information from both sources were
acquired. However, re-genotyping of major susceptibility signals
found by imputation may still be useful as this represents the gold
standard for ascertainment of allelic status of SNPs.
Effects of candidate gene SNPs on asthma risk are modest, not
exceeding a change in risk by more than app. 50% (odds ratios
between 0.58 and 1.50) which is within the expected range for
genetic effects in complex diseases and not significantly different
from susceptibility signals reported by GWAS in atopic diseases
[8–10]: The chromosome 17q21 susceptibility locus shows an
asthma effect size of OR 1.11–1.52 [2], and a further GWAS on
asthma report ORs of 0.88 respectively [9]. Odds ratios for asthma
identified through intermediate phenotypes by GWAS were 0.54
[5] and 1.07–1.16 [6]. A recently reported susceptibility locus for
atopic dermatitis on 11q13.5 shows an overall effect of OR 1.22 [8].
These data indicate that a number of previously suggested asthma
candidate gene SNPs influence asthma susceptibility at a modest
level, comparable to those genes identified through GWAS in
allergy genetics. Effects can be detected in large study populations
but effect size may be minor and significance of effects and effect
direction may vary in smaller studies or be influenced by
environmental factors in specific populations (table 1). Highly
significant p-values of associations in initial GWAS reports may
imply but not guarantee replication of associations in further
cohorts. At the same time, biological candidates such as those
identified through hypothesis driven candidate gene approaches
may not yield p-values significant after correction for multiple
testing in GWAS but may replicate consistently over many
populations tested. In some cases, as shown in table 1, replication
of gene effects on asthma is on a gene level rather than on the
individual SNP level, indicating either that the putatively causal
SNP may not be typed or that gene by environment effects may
modify effects; definitions of asthma phenotypes may vary between
studies and different genetic models may have been applied in
different studies [11]. Publication bias may be present for candidate
genesand couldhaveinfluencedtheselectionofgenesexceedingthe
threshold of 3 positive replications. For all mentioned genes and
susceptibility signals, systematic replications are thus required
before final conclusions can be drawn. Taken all considerations
into account, the strongest evidence for true association between a
previous candidate SNP and asthma in this population exists for
rs528557 in ADAM33, while the signal from chromosome 17q21 is
the most replicated finding from GWAS studies so far.
Our analyses suggest that GWAS is a powerful tool to discover
novel susceptibility loci forcomplex diseases and ithasrecently been
applied very successfully. However, GWAS have limitations that
may be overcome with improvements in SNP coverage and
imputation. At this point GWAS are not designed to finally exclude
potential candidate genes from a role in a specific disease. This is
particularly the case for complex diseases where a single study can
not cover all potential phenotypes, all possible gene-environment
interactions and all different genetic models. Replication in as many
populationsaspossibleisstillimportant,aswellasthe determination
of biological function for candidate genes and SNPs in a specific
disease. This is the challenge for the post-GWAS era.
Methods
Population description
An overview of the population selection for this study is given in
figure 5 and described briefly here. From 2001 to 2007, the
Multicenter Asthma Genetic in Childhood (MAGIC) study
recruited 1255 children in seven German and Austrian clinical
asthma centers located in Bochum, Cologne, Feldkirch, Freiburg,
Munich/Rosenheim, Vienna and Wesel. A pediatric pulmonolo-
gist diagnosed asthma and allergies according to clinical guidelines
and objective measures such as lung function tests, clinical
examination, history, and allergy testing in 865 children (mean
age 11 years, range 3–17 years, 64% male). Children without
asthma but other conditions (such as inflammatory bowel disease)
were also recruited in another leg of the study in the same clinical
centers (n=390) but have not been included in any analysis so far.
All 655 children from the MAGIC study that were included in this
and previous analyses [2] were diagnosed with asthma, were of
German origin and had sufficient high quality DNA available at
the time the genome wide analysis was performed in 2006.
As a reference, a random sample consisting of 800 German
children was drawn from the cross sectional International Study of
Asthma and Allergies in Childhood phase II (ISAAC II). 767 passed
DNA quality control for GWAS and of these, 73 were asthmatics
and 694 were non-asthmatics. The ISAAC II population had been
described in great detail before. In brief, the study assessed the
prevalence of asthma and allergies in schoolchildren aged 9–11
years in Munich and Dresden in 1995 and 1996 [12]. Asthma status
wasbased on the parent’sreportofa physician’s diagnosis of asthma
at least once, or of spastic or asthmatic bronchitis more than once in
self-administered questionnaires.
Written informed consent was obtained from all parents of
children included in these studies and study methods were
approved by the respective ethics committees. All children were
of German origin to control for population admixture [2].
Genotyping
Technical details on GWAS genotyping of our study population
using the Illumina Sentrix HumanHap300 BeadChip have been
published elsewhere [2]. For additional in depth re-genotyping of
candidate gene SNPs, matrix-assisted laser desorption/ionization
time-of flight (MALDI-TOF) mass spectrometry (Sequenom Inc.,
San Diego, USA) was used as previously described [13]. SNPs
failing MALDI-TOF genotyping were genotyped by a TaqManH
MGB biallelic discrimination system as previously described [14].
Deviations from Hardy–Weinberg Equilibrium (HWE) in the
control group were assessed for quality control of genotyping
procedures. Detailed information including specific amplification
and extension primers for all genotyping procedures are provided
by the authors upon request.
Statistical analyses and quality control
Statistical analyses were performed with the PLINK [15]
software package (version 1.04, http://pngu.mgh.harvard.edu/
purcell/plink/) and confirmed with the SAS statistical software
package (version 9.2; SAS, Inc., Cary, NC). All associations of
asthma with SNPs, their accompanying odds ratio and confidence
intervals were evaluated by the additive logistic regression model.
We restricted the analysis to one genetic model (which is the
common model for GWAS) to reduce the problem of multiple
testing. Power calculations were performed with the PGA software
package [16].
We imputed genotypes for all polymorphic HapMap SNPs
(www.hapmap.org) by using a hidden Markov model programmed
in MACH [17]. The method combines genotypes from the study
samples with the HapMap CEU sample (July 2006 phased
haplotype release, called HapMapII and Feb 2009 phased
haplotype release, called HapMapIII) and identifies the stretches
of haplotype shared between the study samples and the HapMap
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be summarized by taking (1) the most likely genotype according to
the posterior probability of the three possible genotypes and (2)
allele dosage, the expected number of copies of the reference allele
(a fractional value between 0 and 2). We used the imputed most
likely genotypes for association analyses.
Exclusion criteria for further analyses were a low genotyping
rate (,95%) with the Illumina Sentrix HumanHap300 BeadChip,
incomplete phenotype information, unusual high heterozygosity,
missing age information or age above 18 years, genetic
identification of cryptic cousin pairs or non-Caucasian origin.
Thus, for further analyses 703 asthmatics, of which 414 were
males and 658 controls (372 males), remained. Table 3 provides
additional clinical information. Background stratification was
measured by a genomic control parameter of 1.01. All markers
which failed the HWE test in controls (p,=0.0001), had low
minor-allele frequencies (,5%) or low genotyping call rates
(,95%) were also excluded. The remaining 300,745 SNPs were
used for further analyses. For re-genotyping of candidate gene
SNPs in children with sufficient DNA available, genotype call rates
of at least 95% were achieved by MALDI-TOF and TaqManH
MGB assays. The software Haploview [18] was used to calculate
linkage disequilibrium (LD) patterns and to select tagging SNPs
(MAF 0.001, r2.0.8). The chi-square test was applied to analyse
deviations from Hardy-Weinberg equilibrium (HWE), with
expected frequencies derived from allele frequencies. The alpha
level was set to 0.0035 to correct for multiple testing of 14 genes
(0.05/14=0.0035).
Supporting Information
Table S1 Gene symbol, references, total number of SNPs and
individual rs numbers of asthma associated SNPs
Figure 5. Study Design and population selection strategy. (ISAAC = International Study for Asthma and Allergies in Childhood; MAGICS = Multicentre
Asthma Genetics in Childhood Study; GWAS = Genome wide Association Study; QC = quality control).
doi:10.1371/journal.pone.0013894.g005
Table 3. Characteristics of the population used for the actual
study consisting of two parts, the Multicentre Asthma
Genetics in Childhood Study (MAGICS) and the International
Study for Asthma and Allergies in Childhood (ISAAC).
MAGICS ISAAC
No.* percentage No.* percentage
male sex 414/631 65.6 372/730 51
age, mean (SD) 10.97 (2.92) 9.62 (0.78)
asthmatic 631/631 100 72/730 9.9
atopic sensitization 498/617 80.9 302/729 41.4
*Number affected/number with data available.
doi:10.1371/journal.pone.0013894.t003
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Table S2 Candidate gene associations with asthma and
comparison between genotyping and imputation results. Odds
ratios, 95% confidence intervals are given for SNP effects. R2 is
given for SNPs were both imputation and genotyping data is
available. Bold font indicates previously reported SNPs, standard
font is tagging SNPs, cursive font indicates SNPs that are neither
tagging nor previously reported SNPs; * p,0.05; **p,0.0035
Found at: doi:10.1371/journal.pone.0013894.s002 (0.10 MB
PDF)
Table S3 Comparison of candidate gene SNP coverage by
GWAS genotyping systems. Number of genotyped SNPs per
candidate gene locus from 5 kb upstream of 1st exon to 5 kb after
last exon are given and in brackets ( ) genotyped or covered SNPs
with previously reported asthma association.
Found at: doi:10.1371/journal.pone.0013894.s003 (0.04 MB
DOC)
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